Get access

Self-Adjuvanting Multicomponent Cancer Vaccine Candidates Combining Per-Glycosylated MUC1 Glycopeptides and the Toll-like Receptor 2 Agonist Pam3CysSer


  • We would like to thank the Australian Research Council for funding (ARC Discovery Project: 0986632) and Dr. Kelvin Picker and Dr. Keith Fisher for technical support.


original image

More sugar with your “T”: The title candidates comprising per-glycosylated MUC1 peptides, a T-cell helper peptide, and an immunoadjuvant were assembled in high yields using iterative pentafluorophenyl ester-mediated fragment condensations. Following immunological evaluation, a tricomponent vaccine bearing clustered glycosylation with the T-antigen was identified (see structure) which elicited high IgG antibody titers in murine models without an external adjuvant.